Titles and Roles

Biography

A Georgia Cancer Coalition Distinguished Cancer Scholar, Jacques Galipeau, MD, FRCP(C) is Adjunct Professor of Hematology and Medical Oncology, Pediatrics & Medicine, Emory School of Medicine and was Co-Director of the Winship Cancer Institute Tumor Immunology-Immunotherapy initiative as well as Director of the Emory Personalized Immunotherapy Center (EPIC). In his 12 year career at McGill University starting in 1997, he initiated and developed a research program in cell and immunotherapy of catastrophic illnesses including cancer, immune and cardiovascular disease. He relocated to Emory University in October 2009 where he established the Emory Personalized Immunotherapy Center (EPIC) whose mission is to develop evidence-based and innovative personalized cell therapies for immune and malignant disorders.

Dr. Galipeau is a member of the Discovery and Developmental Therapeutics Research Program at Winship Cancer Institute. He also holds memberships with International Society of Cell Therapy, American Society of Hematology, American Association of Immunologists, American Society of Transplantation and Society for Immunotherapy of Cancer.

Education

Dr. Galipeau received his Medical Degree from the University of Montreal in 1988. He completed specialty training in Internal Medicine at the McGill-affiliated Jewish General Hospital. He went on to the Tufts-affiliated New England Medical Center in Boston for three years of subspecialty training in Hematology and Oncology, followed by a two-year Scientific Fellowship in Gene Therapy at St. Jude Children's Research Hospital in Memphis, Tennessee. Dr. Galipeau was faculty at McGill University from 1997 to 2011 prior to joining Emory.

Research

Since 1997, Dr. Galipeau has initiated and developed a research program in cell and gene therapy of catastrophic illnesses including cancer, immune and cardiovascular disease. In October 2009, he relocated to Emory University in Atlanta and joined the Departments of Hematology/Medical Oncology & Pediatrics as a Tenured Professor and was given the mandate of developing first-in-human translational studies exploring the use of adult stem cells as a cellular pharmaceutical. His mission is to develop and implement innovative trans-disciplinary translational (bench to bedside) research in cell-based therapeutics, regenerative medicine and tumor immunotherapy.

Consequently, Dr. Galipeau established the Emory Personalized Immunotherapy Center (EPIC) whose mandate is to investigate and develop cellular and biological therapies to manipulate the immune response in a transformative manner with the objective of improving clinical outcomes in cancer and autoimmune disorders. There is a clear aim of driving for first-in-human implementation of personalized cellular medicine clinical trials and we have successfully done so as exemplified by our obtaining a FDA CBER IND (#14825) enabling Emory's first ever clinical trial testing the use of autologous mesenchymal stromal cells for treatment of Crohn's disease (NCT01659762).

Publications

As Dr. Galipeau's publication record shows, he has created a line of investigation which seeks to investigate and develop the use of cell therapy to alter the immune response and has published numerous peer-reviewed manuscripts spanning cell biochemistry, physiology, immunology, genetic engineering and cell therapy translational use in pre-clinical disease models. Dr. Galipeau has extensive experience collaborating with multidisciplinary scientists, specifically in the areas of biology and translational medicine.